Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy?

Which should be the correct treatment for monoclonal gammopathy of renal significance with... International Urology and Nephrology https://doi.org/10.1007/s11255-018-1896-8 NEPHROLOGY - LE T TER TO THE EDITOR Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy? 1 2 Mariana Ciocchini  · Carlos G. Musso Received: 2 May 2018 / Accepted: 15 May 2018 © Springer Science+Business Media B.V., part of Springer Nature 2018 Editor, by: mesangiolysis, microaneurysms, endothelial swelling, cellular proliferation with endothelial or membranopro- Monoclonal gammopathy of renal significance (MGRS) liferative pattern (depending on its degree of evolution) is a recently described hemato-nephrological meta-entity and patchy subcortical renal atrophy according to small induced by monoclonal immunoglobulins (Ig) or humoral artery endarteritis. The presence of thrombi in capillaries is factors secreted by small B-cell clones. MGRS can show a pathognomonic of TMA but their absence does not rule out broad spectrum of renal histopathological patterns which its diagnosis. Moreover, haematological alterations are not can even coexist in the same patient [1, 2]. mandatory for TMA diagnosis [4–6]. C3 glomerulopathy (C3G) and atypical hemolytic uremic C3G and aHUS can overlap, being reported that 6% of syndrome (aHUS), which are the prototype of complement- C3G with monoclonal Ig has TMA. Transitional forms mediated kidney diseases, are characterised http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Urology and Nephrology Springer Journals

Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy?

Loading next page...
 
/lp/springer_journal/which-should-be-the-correct-treatment-for-monoclonal-gammopathy-of-EktzAE7aNK
Publisher
Springer Netherlands
Copyright
Copyright © 2018 by Springer Science+Business Media B.V., part of Springer Nature
Subject
Medicine & Public Health; Nephrology; Urology
ISSN
0301-1623
eISSN
1573-2584
D.O.I.
10.1007/s11255-018-1896-8
Publisher site
See Article on Publisher Site

Abstract

International Urology and Nephrology https://doi.org/10.1007/s11255-018-1896-8 NEPHROLOGY - LE T TER TO THE EDITOR Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy? 1 2 Mariana Ciocchini  · Carlos G. Musso Received: 2 May 2018 / Accepted: 15 May 2018 © Springer Science+Business Media B.V., part of Springer Nature 2018 Editor, by: mesangiolysis, microaneurysms, endothelial swelling, cellular proliferation with endothelial or membranopro- Monoclonal gammopathy of renal significance (MGRS) liferative pattern (depending on its degree of evolution) is a recently described hemato-nephrological meta-entity and patchy subcortical renal atrophy according to small induced by monoclonal immunoglobulins (Ig) or humoral artery endarteritis. The presence of thrombi in capillaries is factors secreted by small B-cell clones. MGRS can show a pathognomonic of TMA but their absence does not rule out broad spectrum of renal histopathological patterns which its diagnosis. Moreover, haematological alterations are not can even coexist in the same patient [1, 2]. mandatory for TMA diagnosis [4–6]. C3 glomerulopathy (C3G) and atypical hemolytic uremic C3G and aHUS can overlap, being reported that 6% of syndrome (aHUS), which are the prototype of complement- C3G with monoclonal Ig has TMA. Transitional forms mediated kidney diseases, are characterised

Journal

International Urology and NephrologySpringer Journals

Published: May 28, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off